Press releases
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
- Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
- Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
- Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.58 |
---|---|
High | 13.58 |
Low | 13.58 |
Bid | 13.53 |
Offer | 13.65 |
Previous close | 13.82 |
Average volume | 182.40 |
---|---|
Shares outstanding | 165.22m |
Free float | 164.42m |
P/E (TTM) | -- |
Market cap | 2.44bn USD |
EPS (TTM) | -0.0129 USD |
Data delayed at least 15 minutes, as of May 17 2024 07:01 BST.
More ▼